ONCT - Oncternal Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
ONCT price evolution
ONCT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.38 | $6.4 | $6.7 | |
| Short term investments | $15.05 | $20.63 | $27.56 | |
| Net receivables | $0.34 | $0.56 | $0.72 | |
| Inventory | ||||
| Total current assets | $15.45 | $23.26 | $28.5 | $36.06 |
| Long term investments | ||||
| Property, plant & equipment | $0.15 | $0.19 | $0.23 | $0.26 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.6 | $0.64 | $0.67 | |
| Total investments | $15.05 | $20.63 | $27.56 | |
| Total assets | $15.6 | $23.86 | $29.14 | $36.73 |
| Current liabilities | ||||
| Accounts payable | $1.2 | $1.9 | $1.46 | $1.15 |
| Deferred revenue | ||||
| Short long term debt | $0.18 | $0.18 | $0.17 | |
| Total current liabilities | $6.45 | $8.05 | $6.12 | $5.2 |
| Long term debt | $0.05 | $0.1 | $0.14 | |
| Total noncurrent liabilities | $0.05 | $0.1 | $1.48 | |
| Total debt | $0.23 | $0.28 | $0.32 | |
| Total liabilities | $6.45 | $8.11 | $6.21 | $6.68 |
| Shareholders' equity | ||||
| Retained earnings | -$223.19 | -$214.73 | -$206.17 | -$197.78 |
| Other shareholder equity | $0 | -$0 | -$0.01 | $0 |
| Total shareholder equity | $15.75 | $22.93 | $30.05 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.7 | $37.14 | $90.77 | $116.74 |
| Short term investments | $27.56 | $26.58 | ||
| Net receivables | $0.63 | $0.18 | ||
| Inventory | ||||
| Total current assets | $36.06 | $67.29 | $92.85 | $118 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.09 | $0.07 | $0.04 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.67 | $1.36 | $0.73 | $0.81 |
| Total investments | $27.56 | $26.58 | ||
| Total assets | $36.73 | $68.65 | $93.58 | $118.81 |
| Current liabilities | ||||
| Accounts payable | $1.15 | $2.92 | $1.96 | $1.14 |
| Deferred revenue | $1.63 | |||
| Short long term debt | $0.17 | $0.09 | $0.07 | $0.04 |
| Total current liabilities | $5.2 | $7.68 | $5.46 | $5.86 |
| Long term debt | $0.14 | |||
| Total noncurrent liabilities | $1.48 | |||
| Total debt | $0.32 | $0.09 | $0.07 | $0.04 |
| Total liabilities | $6.68 | $7.68 | $5.46 | $5.86 |
| Shareholders' equity | ||||
| Retained earnings | -$197.78 | -$158.3 | -$114.13 | -$82.8 |
| Other shareholder equity | $0 | $0.01 | ||
| Total shareholder equity | $30.05 | $60.97 | $88.12 | $112.95 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.8 | $0.57 | $0.3 | |
| Cost of revenue | ||||
| Gross Profit | $0.8 | $0.57 | $0.3 | |
| Operating activities | ||||
| Research & development | $6.61 | $6.06 | $6.67 | |
| Selling, general & administrative | $3.05 | $3.29 | $3.26 | |
| Total operating expenses | $9.66 | $9.35 | $9.93 | |
| Operating income | -$8.86 | -$8.78 | -$9.64 | |
| Income from continuing operations | ||||
| EBIT | -$8.56 | -$8.39 | -$9.16 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.56 | -$8.39 | -$9.16 | |
| Income (for common shares) | -$8.56 | -$8.39 | -$9.16 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.79 | $1.49 | $4.32 | $3.38 |
| Cost of revenue | ||||
| Gross Profit | $0.79 | $1.49 | $4.32 | $3.38 |
| Operating activities | ||||
| Research & development | $29.75 | $32.98 | $24.09 | $12.54 |
| Selling, general & administrative | $12.75 | $13.46 | $11.6 | $8.37 |
| Total operating expenses | $42.5 | $46.44 | $35.68 | $20.92 |
| Operating income | -$41.71 | -$44.95 | -$31.37 | -$17.54 |
| Income from continuing operations | ||||
| EBIT | -$39.48 | -$44.17 | -$31.33 | -$17.23 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$39.48 | -$44.17 | -$31.33 | -$17.23 |
| Income (for common shares) | -$39.48 | -$44.17 | -$31.33 | -$17.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$8.56 | -$8.39 | -$9.16 | |
| Operating activities | ||||
| Depreciation | $0.04 | $0.03 | $0.03 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.38 | $1.36 | $2.22 | |
| Total cash flows from operations | -$5.82 | -$7.44 | -$6.42 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $5.81 | $7.22 | -$1.81 | |
| Total cash flows from investing | $26.68 | $5.81 | $7.22 | -$1.81 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.09 | -$0 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$0.09 | -$0.09 | -$0 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $6.38 | -$0.01 | -$0.3 | -$8.23 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$39.48 | -$44.17 | -$31.33 | -$17.23 |
| Operating activities | ||||
| Depreciation | $0.17 | $0.18 | $0.17 | $0.15 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.5 | $7.43 | $5.88 | $1.56 |
| Total cash flows from operations | -$32.16 | -$36.7 | -$26.59 | -$17.5 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $0.65 | -$26.5 | ||
| Total cash flows from investing | $0.65 | -$26.5 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.07 | $9.58 | $0.62 | $113.88 |
| Net borrowings | $0.3 | |||
| Total cash flows from financing | $1.07 | $9.58 | $0.62 | $114.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$30.45 | -$53.62 | -$25.97 | $96.69 |
News
Fundamentals
| Market cap | $1.56M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.96M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.22 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.39 |
| Quick ratio | N/A |